Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 2 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Lancet Haematol. 2022 Dec;9(12):e906-e918. doi: 10.1016/S2352-3026(22)00289-7. Epub 2022 Oct 27.
Lancet Haematol. 2022.
PMID: 36354020
Thus, lenalidomide can be used for other indications without the major concern of a therapy-related neoplasm. In the multiple myeloma setting, lenalidomide is an effective drug, but patients should be monitored both for haematological and solid tumour SPM. .. …
Thus, lenalidomide can be used for other indications without the major concern of a therapy-related neoplasm. In the mu …
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen Q, Zhou Y, Garcia-Manero G, Loghavi S, Hu AY, Wang S, Bueso-Ramos CE, Kantarjian HM, Medeiros LJ, Hu S.
Xie W, et al.
Ann Hematol. 2020 Mar;99(3):487-500. doi: 10.1007/s00277-020-03909-7. Epub 2020 Jan 31.
Ann Hematol. 2020.
PMID: 32006151
Item in Clipboard
A 14-year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single-centre experience.
Hamilton EM, Nath KD, Vangaveti VN, McCutchan AD, Marsh JL, Birchley AJ, Casey JM, McNamara C, Lai HC, Morris ES, Hodges G, Irving IM.
Hamilton EM, et al.
Intern Med J. 2020 Feb;50(2):214-221. doi: 10.1111/imj.14395.
Intern Med J. 2020.
PMID: 32037713
Key outcomes included overall survival, non-relapse mortality, incidence of therapy-related neoplasm and causes of death. Progression-free survival in the multiple myeloma (MM) subgroup was also assessed. ...
Key outcomes included overall survival, non-relapse mortality, incidence of therapy-related neoplasm and causes of deat …
Item in Clipboard
Cite
Cite